Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

Right Now

Increasing Trends in Biosimilar Market Outlook: Ken Research

The biosimilars market involves of
sales of biosimilars and associated services that are cast-off to treat chronic
sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are
pharmaceuticals that are produced using cell lines and offers no clinical
difference as linked to biologics. The Biosimilars are made once the patent of
biologics is deceased.

According to the report analysis, ‘Biosimilars
Market Global Report 2020-30
’ states that the worldwide biosimilars
market was worth USD 7.79 billion during 2019. It is predicted to augment at a
compound annual growth rate (CAGR) of 31.70% and reach USD 23.63 billion by

Additionally, the production of
fresh insulin biosimilars is trending in the biosimilars market. The foremost
players functioning in the biosimilars market are contributing in generating a
biosimilar of insulin. This is also encouraging competition amongst several
biosimilar producers. For instance, during 2019, Mylan, a U.S-based
pharmaceutical company, in partnership with Biocon, an Indian grounded
biopharmaceutical company launched biosimilar insulin glargine named Semglee.
Also, during 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical
company improved an oral insulin drug named ORMD-0801 to indulgence type 2
diabetes. Thus, corporates in the biosimilars market are underwriting in the
improvement of insulin biosimilar to obtain the profits.

During June 2018, Japan-based Fuji
Pharma Co., Ltd. obtained a 4.2% stake of Alvotech for USD 50 million. The
acquisition comprises Alvotech to advance, produce and supply biosimilars and
Fuji Pharma will sell the biosimilars during Japan. The Alvotech is an
Iceland-based biopharmaceutical organization.

While, the shortage of awareness
about biosimilars amongst the primary care physicians (PCPs) and specialists
restricts the growth of the biosimilars market. Biosimilars are produced from
cell lines and offer the similar effectiveness as biologics. However, shortage
of familiarity with biosimilars decreases the likelihood of suggesting the
drugs to patients which affects the requirement for fresh biosimilars in the
market. For instance, during 2018, according to the PwC's Health Research
Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar
with the biosimilars and 35% were disinclined to prescribe them owing to
concerns involved protection of the follow-on biologic. Thus, the shortage of
awareness about biosimilars amongst the primary care physicians (PCPs) and
specialists limits the growth of the biosimilars market.

Whereas, the effective growth in
the prevalence of chronic diseases such as arthritis, asthma, and cancer is
predicted to be a foremost driver of the biosimilars market. Long working
hours, restricted physical activity, unhealthy eating and drinking habits
underwrite to the pervasiveness of chronic syndromes and biosimilars are
progressively used to cure these chronic syndromes. Biosimilars activate the
immune system rejoinder against the cancer cells thus supporting the immune
system to eradicate the cancer cells from the body. According to a United
Nations article, by 2030 the proportion of worldwide deaths owing to chronic
diseases is predicted to augment to 70% of total deaths. The worldwide burden
of chronic disease is predicted to reach nearly 60%. Therefore, the augment in
the prevalence of chronic diseases is predicted to propel the demand for
biosimilars, thus influencing the biosimilars market.

For More Information, Click on the Link Below:-

Biosimilars Market

Related Reports:-

Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer
Environment and Patent Expiries for Best-Selling Biologics

Biosimilars Market 2019 by Manufacturers, Regions, Type and Application,
Forecast to 2024

Contact Us:-

Ken Research

Ankur Gupta, Head Marketing &


Load More wait